BGLC
BioNexus Gene Lab Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · MY
$1.41
−4.08%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.1M | 7.4M | 9.5M | 9.8M | 10.9M |
| Cost of Revenue | 2.8M | 6.3M | 8.2M | 8.4M | 9.7M |
| Gross Profit | 364.0K | 1.1M | 1.3M | 1.3M | 1.3M |
| Operating Expenses | |||||
| R&D Expense | 54.1K | 50.7K | 47.5K | 55.0K | — |
| SG&A Expense | 1.8M | 4.1M | 4.0M | 3.0M | 1.7M |
| General & Admin Expense | 1.7M | 2.3M | 2.0M | 2.4M | 1.7M |
| Selling & Marketing Expense | (479.9K) | 1.7M | 2.0M | 596.9K | — |
| Other Expenses | 1.1M | 126.4K | (1.2M) | 828.4K | (179.3K) |
| Total Operating Expenses | 3.0M | 4.2M | 2.9M | 3.9M | 1.6M |
| Cost and Expenses | 5.7M | 10.6M | 11.1M | 12.4M | 11.2M |
| Operating Income (EBIT) | (2.6M) | (3.2M) | (1.6M) | (2.6M) | (291.2K) |
| Non-Operating | |||||
| Interest Income | 68.9K | 83.9K | 147.6K | — | — |
| Interest Expense | 6.4K | 19.5K | 21.1K | 13.9K | 12.5K |
| Net Interest Income | 62.6K | 64.3K | 126.5K | (13.9K) | (12.5K) |
| Other Non-Op Income/Expense | 13.2K | 173.8K | (21.1K) | (13.9K) | (12.5K) |
| Non-Operating Income (excl Interest) | (19.6K) | (193.4K) | — | (4.00) | — |
| EBT (Pre-Tax Income) | (2.6M) | (3.0M) | (1.6M) | (2.6M) | (303.7K) |
| Income Tax Expense | — | — | 3.5K | 21.5K | 52.3K |
| Bottom Line | |||||
| Net Income | (2.6M) | (3.0M) | (1.6M) | (2.6M) | (356.0K) |
| Earnings from Cont. Ops | (2.6M) | (3.0M) | (1.6M) | (2.6M) | (356.0K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.6M) | (3.0M) | (1.6M) | (2.6M) | (356.0K) |
| Per Share | |||||
| Basic EPS | ($1.26) | ($1.61) | ($0.90) | ($1.53) | ($0.25) |
| Diluted EPS | ($1.26) | ($1.61) | ($0.90) | ($1.53) | ($0.25) |
| Revenue Per Share | $1.29 | $4.00 | $5.34 | $5.67 | $7.58 |
| Shares | |||||
| Basic Shares Outstanding | 2.4M | 1.9M | 1.8M | 1.7M | 1.4M |
| Diluted Shares Outstanding | 2.4M | 1.9M | 1.8M | 1.7M | 1.4M |
| Profitability Metrics | |||||
| EBITDA | (2.4M) | (2.8M) | (1.4M) | (2.5M) | (185.8K) |
| D&A | 130.4K | 168.3K | 153.1K | 108.4K | 105.4K |
| EBIT | (2.6M) | (3.0M) | (1.6M) | (2.6M) | (291.2K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026